Analysts are intrested in these 5 stocks: ( (KSS) ), ( (NIO) ), ( (OSCR) ), ( (ABEV) ) and ( (APA) ). Here is a breakdown of their recent ratings and the rationale behind them.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kohl’s is experiencing a significant turnaround under the leadership of CEO Michael Bender, as highlighted by analyst Charles Grom from Gordon Haskett Research Advisors. Grom upgraded Kohl’s stock to a Buy rating with a price target of $25, citing the company’s strategic shift back to emphasizing proprietary brands and improving digital sales. Despite past missteps, the company’s recent performance in key performance indicators, such as a 1.0% growth in proprietary brands and a 2.4% increase in digital sales, suggests a promising recovery. With plans to launch MAC in Sephora locations and a focus on value and quality, Kohl’s is poised for continued growth.
Nio, on the other hand, faces challenges as analyst Eugene Hsiao from Macquarie Research downgraded the stock to Hold. The downgrade comes amid policy headwinds and a weaker-than-expected Q4 volume guidance, partly due to the phase-out of government subsidies. Despite a positive vehicle margin and cost controls, the lack of new model launches until mid-2026 and cautious management tone regarding EV policy measures have tempered expectations. The market remains focused on volume momentum, and while Nio’s unique BaaS offering provides an edge, competition in the high-end BEV market is expected to remain fierce.
Oscar Health is on an upward trajectory, with analyst Jessica Tassan from Piper Sandler upgrading the stock to Buy. Tassan’s analysis highlights Oscar Health’s strategic pricing and product design in response to potential market challenges, such as the expiration of E-APTCs. With a focus on expanding market share and margins, Oscar Health’s CY26 product portfolio is structured for retention and margin recapture. The company’s innovative offerings, like HelloMeno, and a new bonus program for brokers are expected to drive growth, with a projected adjusted EBITDA of $404 million by CY27.
Ambev SA has been downgraded to Hold by analyst Nadine Sarwat from Bernstein, who cites overblown expectations as the reason for the downgrade. Despite strong long-term fundamentals and impressive cost control, the stock’s recent rally has led to concerns about near-term risks. A proposed dividend tax and potential extraordinary dividend have created uncertainty, prompting a recommendation for investors to take profits. Ambev’s market leadership in Brazil and exposure to emerging markets remain strong, but clarity on Q4 trading and cash return strategy is needed for a more attractive entry point.
APA Corporation has been initiated at Buy by analyst Neal Dingmann from Energy and Power Technologies, who highlights the company’s large asset base and strategic partnerships. APA’s significant holdings in the Permian Basin, Egypt, and a joint venture with TotalEnergies in Suriname position the company for growth. With a focus on capital discipline and exploration, APA is expected to deliver solid shareholder returns. The company’s financials are strong, with a low leverage ratio and a favorable valuation compared to peers, suggesting a potential upside in share value.